|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||
  International Journal of DermatologyVolume 28 Issue 6, Pages 410 - 412 Published Online: 31 May 2007 Journal compilation © 2010 International Society of Dermatology The Official Journal of the International Society of Dermatology
Abstract | References | Full Text: PDF (Size: 3577K) | Related Articles | Citation Tracking  Double-Blind Comparison of Itraconazole with Griseofulvin in the Treatment of Tinea Corporis and Tinea Cruris This multicenter study was conducted in several cities throughout Belgium. J. Van Cutsem, Janssen Pharmaceutica, conducted the mycology invesstigations. Copyright 1989 Blackwell Science Ltd ABSTRACT
Seventy-eight patients with tinea corporis or tinea cruris participated in a double-blind study with either 100 mg itraconazole or 500 mg ultramicromized griseofulvin for 15 consicutive days. Clinical outcome was significantly in favor of itraconazole at completion of treatment (72% responce rate vs. 51%) and at the follow-up visit(91% response vs. 64%). The most important difference berween both treatment was the mycologic outcome, for which itraconazole showed a cure rate oc 87% compared to 57% for griseofulvin 2 weeks after comparison of therapy. It is suggested that 100 mg of itraconazole orally daily is significantly more effective than 500 mg of griseofulvin once daily for 15 days in the treatment of glabrous skin infections. Both drugs were well tolerated. | 
|
